EBioMedicine (Feb 2020)
Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112]
- Pinar Kanlikilicer,
- Recep Bayraktar,
- Merve Denizli,
- Mohammed H. Rashed,
- Cristina Ivan,
- Burcu Aslan,
- Rahul Mitra,
- Kubra Karagoz,
- Emine Bayraktar,
- Xinna Zhang,
- Cristian Rodriguez-Aguayo,
- Amr Ahmed El-Arabey,
- Nermin Kahraman,
- Seyda Baydogan,
- Ozgur Ozkayar,
- Michael L. Gatza,
- Bulent Ozpolat,
- George A. Calin,
- Anil K. Sood,
- Gabriel Lopez-Berestein
Affiliations
- Pinar Kanlikilicer
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Recep Bayraktar
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA
- Merve Denizli
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA
- Mohammed H. Rashed
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA
- Cristina Ivan
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Burcu Aslan
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Rahul Mitra
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Kubra Karagoz
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- Emine Bayraktar
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA
- Xinna Zhang
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Cristian Rodriguez-Aguayo
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Amr Ahmed El-Arabey
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt
- Nermin Kahraman
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA
- Seyda Baydogan
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA
- Ozgur Ozkayar
- Hacettepe University, Ankara, Turkey
- Michael L. Gatza
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- Bulent Ozpolat
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- George A. Calin
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Anil K. Sood
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Gabriel Lopez-Berestein
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Corresponding author at: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA.
- Journal volume & issue
-
Vol. 52
